<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37469">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618759</url>
  </required_header>
  <id_info>
    <org_study_id>DSXS 1505</org_study_id>
    <nct_id>NCT02618759</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the therapeutic efficacy and safety of DSXS
      compared to a Placebo (vehicle) in patients with mild to moderate plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the therapeutic efficacy and safety of dsxs topical spray, 0.15% (Taro
      Pharmaceuticals, U.S.A., Inc.) compared to a Placebo (vehicle) spray (Taro Pharmaceuticals,
      U.S.A., Inc.) in patients with mild to moderate plaque psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 28, 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients in each treatment group that have clinical success</measure>
    <time_frame>28 Days</time_frame>
    <description>the proportion of patients in each treatment group that have clinical success (Clinical Success is at least a 2-grade improvement from the baseline IGA score, i.e. 0 or 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of patients in each treatment group that have Treatment Success for the Target Lesion</measure>
    <time_frame>28 Days</time_frame>
    <description>The proportion of patients in each treatment group that have Treatment Success for the Target Lesion (Treatment Success for the Target Lesion (a score of 0 or 1 for each of the three signs and symptoms (i.e., erythema, scaling and plaque elevation))</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>DSXS1505</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the therapeutic efficacy and safety of DSXS topical spray, 0.15%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible patients will be randomized in a 1:1 ratio to Test or Placebo product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSXS</intervention_name>
    <description>active treatment</description>
    <arm_group_label>DSXS1505</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo treatment</description>
    <arm_group_label>DSXS1505</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and non-pregnant females, 12 years of age or older, with a confirmed diagnosis
             of mild to moderate plaque psoriasis

        Exclusion Criteria:

          -  patient is&lt; 12 years old.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Yantovskiy</last_name>
    <role>Study Director</role>
    <affiliation>Taro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taro Pharmaceuticals USA Inc.</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>November 1, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
